Quick Verdict
Avalo Therapeutics reported a Q2 2026 net loss of $0.83 per share on no reported product revenue, versus a $1.92 loss per share a year earlier. Shares closed down 0.74% at $18.70 on August 6 and were unchanged after hours. The key positive was $472.2 million in liquidity.
About Avalo Therapeutics
Avalo Therapeutics, Inc. (Nasdaq: AVTX) is a Wayne, Pennsylvania-based clinical-stage biotechnology company founded in 2011. It develops therapies targeting the interleukin-1 beta (IL-1β) pathway for immune-mediated inflammatory diseases. Its lead candidate, abdakibart, is being prepared for a registrational Phase 3 program in hidradenitis suppurativa (HS), following positive Phase 2 LOTUS trial data. Avalo is also advancing AVTX-010, a longer-acting next-generation anti-IL-1β antibody.
At the August 6 close, Avalo’s market capitalization was approximately $211.2 million; its price-to-earnings ratio was not meaningful because the company is loss-making, and it reported no dividend yield. The market capitalization is materially below the company’s June 30 cash, cash equivalents, and investments of $472.2 million, although biotech valuation also reflects expected clinical-development spending, dilution risk, and execution risk.
Top Financial Highlights
- Net loss: $36.4 million, compared with a $20.8 million loss in Q2 2025.
- Basic and diluted loss per share: $0.83, versus $1.92 in Q2 2025.
- Research and development expense: $23.4 million, up $9.3 million year over year.
- General and administrative expense: $8.1 million, up $2.9 million year over year.
- Total operating expenses: $31.5 million, up from $19.3 million.
- Operating loss: $31.5 million, versus $19.3 million a year earlier.
- Gross margin: N/A, as the company did not report product revenue or cost of revenue.
- Net cash used in operating activities: $37.7 million for the first six months of 2026.
- Cash, cash equivalents, and investments: $472.2 million as of June 30, 2026.
- Financing: the Q2 equity offering generated approximately $405.0 million in net proceeds.
- Guidance: existing liquidity is expected to fund operations into 2029.
- Pipeline milestone: registrational Phase 3 initiation for abdakibart in HS is targeted for H1 2027; AVTX-010’s IND submission is also planned for H1 2027.
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
(source: ir.avalotx.com)
Beat or Miss?
Avalo did not provide analyst-consensus revenue or EPS estimates in its earnings release, so a formal earnings beat-or-miss conclusion cannot be made from the company’s primary disclosure. The operational read-through was constructive—positive Phase 2 data and substantial financing runway—but the quarterly loss widened because of higher R&D, G&A, and other expenses.
| Metric | Reported | Difference/Analysis |
| Revenue | Not reported | No consensus comparison available |
| Diluted EPS | ($0.83) | Consensus estimate not disclosed in the release |
| Net loss | -$36.4 million | Loss widened from $20.8 million in Q2 2025 |
| R&D expense | $23.4 million | Increased $9.3 million, including a $10.0 million abdakibart development milestone |
| Cash and investments | $472.2 million | Management expects runway into 2029 |
What Leadership Is Saying
“In the second quarter, we achieved the key objectives that positioned Avalo for its next phase of growth… Our focus now is execution – starting with advancing abdakibart… toward Phase 3 initiation in HS as well as building a broader IL-1β franchise.” — Garry Neil, MD, Chief Executive Officer
Historical Performance
| Category | Q2 2026 | Q2 2025 | Change (%) |
| Net loss | -$36.4 million | -$20.8 million | Loss widened 75.1% |
| R&D expense | $23.4 million | $14.1 million | 66.40% |
| G&A expense | $8.1 million | $5.2 million | 54.50% |
| Total operating expenses | $31.5 million | $19.3 million | 63.20% |
| Loss per share | ($0.83) | ($1.92) | Loss per share narrowed 56.8% |
The improvement in per-share loss does not reflect an improvement in absolute profitability: weighted-average common shares rose to 43.6 million from 10.8 million, largely following the equity financing and other share issuances.
Competitor Historical Performance
The peer set includes Arcus Biosciences and Crinetics Pharmaceuticals, among other biotechnology companies. These companies have different products, development stages, revenue sources, and accounting profiles; the table is therefore directional rather than directly comparable to Avalo’s pre-commercial operating model.
| Category | Q2 2026 | Q2 2025 | Change (%) |
| Avalo net loss | -$36.4 million | -$20.8 million | Loss widened 75.1% |
| Avalo operating expenses | $31.5 million | $19.3 million | 63.20% |
| Arcus revenue | $41.0 million | $160.0 million | -74.40% |
| Arcus EPS | ($0.72) | ($0.08) | Loss per share widened |
| Crinetics revenue | $25.1 million | $1.0 million | 2336% |
| Crinetics EPS | ($1.14) | ($1.23) | Loss per share narrowed 7.3% |
Arcus and Crinetics both exceeded the consensus revenue estimates shown in the available Q2 earnings-history data, while Avalo’s release did not disclose a consensus-comparison figure.
How the Market Reacted
AVTX closed at $18.70 on August 6, down $0.14, or 0.74%, and remained at $18.70 in after-hours trading. The muted after-hours move suggests investors were balancing a widening absolute quarterly loss against positive Phase 2 execution, a planned 2027 Phase 3 program, and an unusually large cash position relative to the company’s market capitalization. This is an inference from the reported market data and release, not a confirmed attribution of the day’s price movement.
Sources
